Myelin disorders

Neuropathology and Applied Neurobiology

Volumn 24, Issue 2, 1998, Pages 87-90

  Huxley, C ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; MYELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; DEMYELINATING DISEASE; GENE MUTATION; GENETIC MODEL; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN CELL; MOUSE; MYELINATION; NONHUMAN; PELIZAEUS MERZBACHER DISEASE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0031900475     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.1998.00033.x     Document Type: Conference Paper

References (30)

1. Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 1995; 11: 274-80
2. Bergoffen J, Scherer SS, Wang S et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993; 262: 2039-42
3. Boison D, Stoffel W. Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. Proc Natl Acad Sci USA 1994; 91: 11709-13
4. Bosse F, Zoidl G, Wilms S, Gillen CP, Kuhn HG, Muller HW. Differential expression of two mRNA species indicates a dual function of peripheral myelin protein PMP22 in cell growth and myelination. J Neurosci Res 1994; 37: 529-37
5. Ellis D, Malcolm S. Proteolipid protein gene dosage effect in Pelizaeus-Merzbacher disease. Nature Genet 1994; 6: 333-4
6. Fabbreti E, Edomi P, Brancolini C, Schneider C. Apoptotic phenotype induced by overexpression of wild-type gas3/PMP22: its relation to the demyelinating peripheral neuropathy CMT1A. Genes Dev 1995; 9: 1846-56
7. Gow A, Lazzarini RA. A cellular mechanism governing the severity of Peliaeus-Merzbacher disease. Nature Genet 1996; 13: 422-8
8. Huxley C. Mammalian artificial chromosomes: a new tool for gene therapy. Generapy 1994; 1: 7-12
9. Huxley C, Passage E, Manson A et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 1996; 5: 563-9
10. Ionasescu VV, Ionasescu R, Searby C, Neahring R. Dejerine-Sottas disease with de novo dominant point mutation of PMP22 gene. Neurology 1995; 45: 1766-7
11. Kagawa T, Ikenaka K, Inoue Y et al. Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron 1994; 13: 427-42
12. Li C, Tropak MB, Gerlai R et al. Myelination in the absence of myelin-associated glycoprotein. Nature 1994; 369: 747-50
13. Magyar JP, Martini R, Ruelicke T et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci 1996; 16: 5351-60
14. Martini R, Zielasek J, Toyka KV, Giese KP, Schachne M. Protein zero (Po) -deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nature Genet 1995; 11: 281-6
15. Montag D, Giese KP, Bartsch U et al. Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron 1994; 13: 229-46
16. Nelles E, Butzler C, Jung D et al. Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci USA 1996; 93: 9565-70
17. Nicholson GA, Valentijn LJ, Cherryson AK et al. A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies. Nature Genet 1994; 6: 263-6
18. Patel PI, Lupski JR. Charcot-Marie-Tooth disease: a new paradigm for the mechanism of inherited disease. Trends in Genet 1994; 10: 128-33
19. Readhead C, Schneider A, Griffiths I, Nave K-A. Premature arrest of myelin formation in transgenic mice with increased proteolipid gene dosage. Neuron 1994; 12: 583-95
20. Roa BB, Dyck PJ, Marks HG, Chance PF, Lupski JR. Dejerine-Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene. Nature Genet 1993; 5: 269-73
21. Roa BB, Garcia CA, Suter U et al. Charcot-Marie-Tooth disease type 1A association with a spontaneous point mutation in the PMP22 gene. New Eng J Med 1993; 329: 96-101
22. Schneider A, Griffiths IR, Readhead C, Nave K-A. Dominant-negative action of the jimpy mutation in mice complemented with an autosomal transgene for myelin proteolipid protein. Proc Natl Acad Sci USA 1995; 92: 4447-51
23. Sereda M, Griffiths I, Pühlhofer A et al. A transgenic rat model of Charcot-Marie-Tooth Disease. Neuron 1996; 16: 1049-60
24. Snipes GJ, Suter U. Molecular anatomy and genetics of myelin proteins in the peripheral nervous system. J Anat 1995; 186: 483-94
25. Suter U, Moskow JJ, Welcher AA et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci USA 1992; 89: 4382-6
26. Suter U, Welcher AA, Ozcelik T et al. Trembler mouse carries a point mutation in a myelin gene. Nature 1992; 356: 241-4
27. Valentijn LJ, Baas F, Wolterman RA et al. Identical point mutations of PMP-22 in trembler-J mouse and Charcot-Marie-Tooth disease type 1A. Nat Genet 1992; 2: 288-90
28. Valentijn LJ, Ouvrier RA, van den Bosch NH, Bolhuis PA, Baas F, Nicholson GA. Dejerine-Sottas neuropathy is associated with a de novo PMP22 mutation. Hum Mutat 1995; 5: 76-80
29. Warner LE, Hilz MJ, Appel SH et al. Clinical phenotypes of different MPZ (Po) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron 1996; 17: 451-60
30. Zoidl G, Blass-Kampmann S, D'Urso D, Schmalenbach C, Müller HW. Retroviral-mediated gene transfer of the peripheral myelin protein PMP22 in Schwann cells: modulation of cell growth. EMBO J 1995; 14: 1122-8